Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition

Bromodomain inhibition comprises a promising therapeutic strategy in cancer, particularly for hematologic malignancies. To date, however, genomic biomarkers to direct clinical translation have been lacking. We conducted a cell-based screen of genetically-defined cancer cell lines using a prototypica...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Puissant, Alexandre, Frumm, Stacey M., Alexe, Gabriela, Bassil, Christopher F., Qi, Jun, Chanthery, Yvan H., Nekritz, Erin A., Zeid, Rhamy, Gustafson, W. Clay, Greninger, Patricia, Garnett, Matthew J., McDermott, Ultan, Benes, Cyril H., Kung, Andrew L., Weiss, William A., Bradner, James E., Stegmaier, Kimberly
Formato: Artigo
Idioma:Inglês
Publicado: 2013
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3672953/
https://ncbi.nlm.nih.gov/pubmed/23430699
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-12-0418
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares